Results 251 to 260 of about 3,286,390 (370)

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

Molecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu, Fenglin Shen, Yang Liu, Ziqing Zhong, Yongling Chen, Zhiyuan Xia, Cuiju Mo, Hongxiu Yu   +7 more
wiley   +1 more source

Stem cell therapy use in patients with dementia: a systematic review. [PDF]

Int J Emerg Med
Uwishema O, Ghezzawi M, Wojtara M, Esene IN, Obamiro K.   +4 more
europepmc   +1 more source

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy [PDF]

, 1980
Philip C. Hoffman, Harvey M. Golomb, Jacob D. Bitran, Tom R. DeMeester, Lionel Cohen, Melvin L. Griem, Judith A. Cooksey, Uri Mintz, Leo I. Gordon, Richard K. Desser, Ann Kinnealey, Corinne A. Sovik   +11 more
openalex   +1 more source

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

Molecular Oncology, Volume 19, Issue 5, Page 1404-1421, May 2025.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock, Lina Benzien, Sandra Lange, Maja Huehns, Alexandra Runge, Catrin Roolf, Anett Sekora, Gudrun Knuebel, Hugo Murua Escobar, Christian Junghanss, Anna Richter   +10 more
wiley   +1 more source

Immunomodulatory Effects of Curcumin on CAR T-Cell Therapy. [PDF]

Antioxidants (Basel)
Limsakul P, Srifa P, Huang Z, Zhu L, Wu Y, Charupanit K.   +5 more
europepmc   +1 more source

SIDE EFFECTS OF INTERFERON-α (INF-α) THERAPY FOR RENAL CELL CARCINOMA

, 1989
Yoshihiro Totsuka, Mikio Kobayashi, HIROSHIGE MATSUO, Kyoichi Imai, Zenichi Ito, Hidetoshi Yamanaka   +5 more
openalex   +2 more sources

Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors [PDF]

, 1989
Helen Griffiths, V Brennan, J Lea, C Bunch, M Lee, H Chapel   +5 more
openalex   +1 more source

Polyfunctional CD8+CD226+RUNX2hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Molecular Oncology, Volume 19, Issue 5, Page 1347-1370, May 2025.
CD226+CD8+ T cells express elevated levels of RUNX2, exhibit higher proliferation capacity, cytokines and cytolytic molecules expression, and migratory capacity. In contrast, CD226−CD8+ T cells display an exhausted phenotype associated with the increased expression of co‐inhibitory receptors and impaired effector functions.
Maryam Rezaeifar, Shima Shahbaz, Anthea C. Peters, Spencer B. Gibson, Shokrollah Elahi   +4 more
wiley   +1 more source

Humanizing CAR T-cell therapy in B-ALL. [PDF]

Blood Adv
Faramand R, Muffly L.
europepmc   +1 more source

Morphologic and clinical determinants of response to therapy in small cell carcinoma of the lung [PDF]

, 1983
James A. Strauchen, Barbara M. Egbert, Jon C. Kosek, Roy MacKintosh, Dayton S. Misfeldt   +4 more
openalex   +1 more source